ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer immunotherapies, today announced the appointment of Scott Tarriff to the Company’s Board of Directors. Mr. Tarriff, who serves as President, Chief Executive Officer and a Director of Eagle Pharmaceuticals, brings more than 25 years of pharmaceutical industry experience to ZIOPHARM.
“Scott’s leadership experience extends from research and development to regulatory and commercial strategy, all of which will be invaluable to ZIOPHARM as its pipeline of leading-edge viro- and cell-based cancer immunotherapies expands,” said Sir Murray Brennan, M.D., Lead Director of ZIOPHARM. “We look forward to Scott’s contributions as a Director at this important stage of growth for the Company.”
Mr. Tarriff is the Founder, President, and Chief Executive Officer of Eagle Pharmaceuticals, a specialty pharmaceutical company focused on developing and commercializing injectable products. Prior to joining Eagle, Mr. Tarriff held various executive positions at Par Pharmaceutical Companies, Inc. including serving as President and Chief Executive Officer from September 2003 to September 2006, after joining Par in 1998. Mr. Tarriff also served on Par’s Board of Directors from 2002 to September 2006. Prior to that, Mr. Tarriff held various positions with Bristol-Meyers Squibb, a publicly-traded biopharmaceutical company, including Senior Director of Marketing. Mr. Tarriff has served as a director of Synthetic Biologics, Inc., a publicly traded biotechnology company, since February 2012 and previously served on the Board of Directors of Clinical Data, Inc., a publicly-traded pharmaceutical company, from September 2009 to April 2011 when Clinical Data was acquired by Forest Laboratories, Inc. Mr. Tarriff holds a M.B.A. from Rider College and a B.S. in marketing from Pennsylvania State University. (Original Source)
Shares of Ziopharm Oncology closed last Friday at $10.96. ZIOP has a 1-year high of $14.40 and a 1-year low of $2.31. The stock’s 50-day moving average is $10.11 and its 200-day moving average is $10.91.
On the ratings front, Ziopharm Oncology has been the subject of a number of recent research reports. In a report issued on September 17, Griffin Securities analyst Keith Markey reiterated a Buy rating on ZIOP, with a price target of $21, which implies an upside of 91.6% from current levels. Separately, on August 10, J.P. Morgan’s Cory Kasimov reiterated a Hold rating on the stock .
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Keith Markey and Cory Kasimov have a total average return of -19.2% and -3.2% respectively. Markey has a success rate of 15.8% and is ranked #3611 out of 3759 analysts, while Kasimov has a success rate of 37.3% and is ranked #3355.
ZIOPHARM Oncology Inc is a biopharmaceutical company. The Company is engaged in the acquiring, developing and commercializing portfolio of cancer therapies that can address unmet medical needs through synthetic biology.